HopeStage
Back to all studies
CompletedNCT00485407

Increasing atomoxetine for ADHD symptoms that remain after treatment

About this titleRead the official source — NCT00485407
Medication studyAges 6–16United States + Canada
The study in practice

Understand this study

Who was this study for?

Listed age limits: 6 years to 16 years.

Listed locations
Scottsdale and 1 more locationSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJuly 2003
Recruitment status
Completed
Enrollment listed in the registry
377
Sponsor
Eli Lilly and Company
Sponsor type
Other organization
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, Canada
Age range
From 6 Years to 16 Years
Official registry ID
NCT00485407
Official title
Show the full official title

Guiding Dose Increases In Patients Incompletely Responsive to Usual Doses of Atomoxetine by Determining Plasma Atomoxetine Concentrations: a Randomized, Double-Blind Study

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Scottsdale, United States · Vancouver, Canada

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Eli Lilly and Company.

Did this study involve medication?

Yes. The study involved medication, including Atomoxetine Hydrochloride.

Who was this study for?

Listed age limits: 6 years to 16 years.

Want to explore more studies?

Explore studies